Results 121 to 130 of about 20,923 (159)

Empagliflozin in HNF1A-MODY (MODY3): A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. [PDF]

Diabetes Care
Maagensen H, Høyerup SO, Jensen JS, Thuesen ACB, Forman JL, Thomsen HH, Vestergaard H, Knop FK, Hansen T, Hædersdal S, Støy J, Vilsbøll T.   +11 more
europepmc   +1 more source

Comparative 24-month cardiovascular outcomes and biomarker trajectories with semaglutide, empagliflozin, and sitagliptin in people with obesity and type 2 diabetes: a multicenter real-world study. [PDF]

Ther Adv Endocrinol Metab
Chen JC, Liu KW, Huang YN, Meyerowitz-Katz G, Tsai TH, Su PH.   +5 more
europepmc   +1 more source

Cost-utility analysis of simultaneous initiation of finerenone and empagliflozin for type 2 diabetes mellitus complicated with chronic kidney disease. [PDF]

Front Pharmacol
Liu Q, Lu J, Chuan F, Zhao R, Xiong N, Wang Z, Zhang J, Lai L.   +7 more
europepmc   +1 more source

Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses. [PDF]

Front Endocrinol (Lausanne)
Jun JE, Oh DH, Jeong IK, Ryu HJ, Hwang YC, Ahn KJ, Chung HY, Kim KP.   +7 more
europepmc   +1 more source

Effects of Empagliflozin Combined with Anaerobic, Aerobic, and Endurance Swimming Protocols on Cardiac Structure and Electrophysiology in Healthy Rats. [PDF]

J Clin Med
Yavuz S, Kilic Ş, Asal S, Babaoglu M, Demirtaş C, Yildirim M, Altay S, Orhan AL.   +7 more
europepmc   +1 more source

Organ-Specific Efficacy of Postischemic Empagliflozin in Acute Stroke and Myocardial Infarction Using Preclinical Models. [PDF]

J Am Heart Assoc
Li J, Dai W, Alavi R, Carreno J, Arakaki X, Pahlevan NM, Kloner RA.   +6 more
europepmc   +1 more source

Cardiorenal Outcomes of Empagliflozin Versus Dapagliflozin in Secondary Prevention Among Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Nationwide Cohort Study. [PDF]

Diabetes Obes Metab
Park S, Jung J, Jeong J, Jang MH, Kim YG, Ann SH, Kim SJ, Han S, Park GM.   +8 more
europepmc   +1 more source

SGLT2 Inhibitors in Nephrolithiasis: Emerging Evidence and What Urologists Need to Know. [PDF]

Med Sci (Basel)
Ivănuță M, Puia D, Ivănuță AM, Haută A, Nistor I, Pricop C.   +5 more
europepmc   +1 more source

Early-Onset Euglycemic Diabetic Ketoacidosis Following Empagliflozin Initiation Triggered by Acute Influenza and a Ketogenic Diet. [PDF]

Cureus
Meyer MS, Ramesh S, Rammouni Y, Lasry S, Sawan H, Zakaria K.   +5 more
europepmc   +1 more source

Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation. [PDF]

Diabetes Obes Metab
Ljungberg C, Bonnesen K, Schmidt M, Vandenbroucke-Grauls C, Dalager-Pedersen M, Sørensen HT, Nørgaard M, Thomsen RW.   +7 more
europepmc   +1 more source